Our stories highlight the impact of our work on people’s lives and how access to affordable quality treatment brings hope and a future. Our work is for people, and in all that we do, we keep the needs of the end user in mind. Through this section, we share the voices of our partners on our joint mission to make sure no one is left behind.
RSV causes severe illness and pneumonia in young children, particularly in low- and middle-income countries. MPP is exploring how voluntary licensing could support earlier, more affordable access to new RSV medicines. We speak to Carlo Giaquinto, Professor of Paediatrics, President of the Penta Foundation and coordinator of the Penta ID Network, an international research collaboration […]
12 November 2026
Keyword